Private finance: Cardior Pharmaceuticals, DiA Imaging Analysis, Elixiron Immunotherapeutics, Speclipse, EpiEndo Pharmaceuticals, Ranok Therapeutics

China: Ranok Therapeutics, an emerging biopharmaceutical company focused on developing therapies for cancer and other serious diseases, has secured a total of US$40m through a Series B funding round denominated in both dollars and Chinese yuan. The financing was led by Lapam Capital and Shanghai Healthcare Capital, with additional participation from Wu Capital, Zhongguancun Kaiyuan…

You must be a HMI Subscriber to view this content.

Subscribe Now »